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Summary Thirty-five patients with prostate cancer were examined for micrometastases to the bone marrow using reverse
transcription-polymerase chain reaction (RT-PCR) with primers specific for the prostate-specific antigen (PSA) gene. Of nine patients with
bone metastases detectable by bone scan imaging, five patients had PSA mRNA expression in the bone marrow detectable by RT-PCR. Of
26 patients with negative bone scan findings, seven patients had PSA mRNA expression detectable in the bone marrow. RT-PCR could
detect micrometastatic prostate cancer cells in the bone marrow that were not detectable by bone scan imaging. Of 16 patients with a serum
PSA concentration of 25 ng ml-1 or greater, only nine (56.3%) had bone metastases detected by bone scans. Ofthe remaining seven patients,
five had micrometastases to the bone marrow detected by RT-PCR. Overall, 14 of 16 patients (87.5%) with a serum PSA concentration of 25
ng ml-' or greater had metastatic bone diseases including bone marrow micrometastases. Of 19 patients with a serum PSA concentration of
less than 25 ng ml-', two (10.5%) had only micrometastatic disease detected by RT-PCR. A significant correlation was observed between the
incidence of bone involvement and the serum PSA concentration. This study suggests that RT-PCR will potentially develop into a relevant
tool to assess bone involvement including bone marrow micrometastases and establish a precise correlation between serum PSA
concentration and metastatic bone disease in patients with prostate cancer.
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The most common haematogenous metastasis from prostate
cancer is to the bone. In clinical management of patients with
prostate cancer, recognition ofmetastatic spread to the bone is crit-
ical in therapeutic options. Curative procedures, such as radical
prostatectomy or radiation therapy directed at the primary tumour,
should only be used in patients with localized prostate cancer.
Radionuclide bone scan imaging is a useful diagnostic test for
detecting prostate cancer metastases. However, approximately
30% ofpatients with a negative bone scan will develop metastatic
disease despite primary treatment (Schellhammer, 1988; Lerner et
al, 1991). Bone destruction, as detected by bone scan imaging, is a
late event in the development of metastases. Bone scan imaging
and other radiological techniques do not have the sensitivity to
detect micrometastatic prostate cancer cells in the bone. Serum
prostate-specific antigen (PSA) concentration is considered to be
the most meaningful and useful marker for prostate cancer and
increases proportionally with advancing clinical stage (Osterling,
1991). In addition, Chybowski et al (1991) have reported that
patients with a low serum PSA concentration rarely have skeletal
metastases. However, a high serum PSA concentration does not
predict bone metastases because a substantial portion of patients
with a high serum PSA concentration do not have bone metastases
detectable by bone scan imaging (Osterling, 1991; Kleer et al,
1993). Failure to predict bone metastasis using the pretreatment
serum PSA concentration might be attributed to the inability of
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conventional radiological scans to detect early bone metastases. To
perform more accurate clinical assessments of bone metastases,
detection methods for metastatic cells need to be sensitive and
specific. The advent ofmolecular biotechnology is timely with the
development of the highly sensitive reverse transcription-poly-
merase chain reaction (RT-PCR)-based assay for detecting
micrometastatic prostate cancer cells (Moreno et al, 1992;
Deguchi et al, 1993; Katz et al, 1994; Wood et al, 1994a). In our
previous study, lymph nodes from patients with prostate cancer
were evaluated for micrometastases using RT-PCR, and the pres-
ence of micrometastatic cells that were difficult to observe using
traditional morphological and immunohistochemical analysis was
demonstrated (Deguchi et al, 1993).
The presence of prostate cancer cells in the bone marrow is the
first and essential step in the development of bone metastases of
prostate cancer. In this study, we detected PSA mRNA expression
in bone marrow aspirates by RT-PCR to determine micrometas-
tases ofprostate cancer to the bone and correlated the pretreatment
serum PSA concentration with metastatic bone disease.
MATERIALS AND METHODS
Patients
Thirty-five Japanese patients with prostate cancer confirmed by
histology were recruited into the study. The stage of the disease
was categorized according to the TNM staging system (Schoder et
al, 1992). No patient was previously treated with hormone therapy,
radiation therapy or chemotherapy. The serum PSA concentration
was determined using an enzyme immunoassay (Markit-M PA Kit;
Dainippon Pharmaceutical, Osaka, Japan) (Kuriyama et al, 1993)
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Figure 1 Detection of mRNA from the prostate biopsy specimen (lanes 1 and 2) and from the bone marrow specimen (lanes 3 and 4) in the patient with
clinically localized prostate cancer (T2cNO). RT-PCR was performed on each of these specimens, using primers specific for PSA mRNA (lanes 1 and 3) or for
I8-actin (lanes 2 and 4). Negative control reactions for RT-PCR using primers for PSA (lane Np) and for j-actin (lane Na) were performed without added mRNA.
Marker lane (M) was loaded with Hae Ill-digested 0X174 DNA. bp, Base pair
before prostate biopsy, surgical management and bone marrow
aspiration. Bone scintigraphy was performed on all patients. Total
body scans were obtained after intravenous administration oftech-
netium-99m-labelled methylene diphosphonate. Bone scans were
analysed by a radiologist who was unaware of any results of the
bone marrow examination. If there was any uncertainty as to
whether an area ofincreased uptake ofthe radionuclide was due to
benign disease or metastatic prostate cancer, radiographs or
computerized tomographs were obtained. The prostate specimens
were examined for PSA mRNA expression using RT-PCR
(Deguchi et al, 1993), and prostate cancer cells in the prostate
specimens were assessed for PSA expression by immunohisto-
chemistry with anti-PSA antibody (Deguchi et al, 1991).
Of26patients withnegative bone scan findings, twopatients with
locally extensive prostate cancer (T3 tumour) and fourpatients with
clinically localized prostate cancer (T2 tumour) underwent prostate-
ctomy with pelvic lymphadenectomy after 3 months' neoadjuvant
hormone therapy (Fairetal, 1993), and seven patients with T2 orTl
Table 1 Bone marrow micrometastases in 35 patients with prostate cancer
according to clinical stages
Clinical stagea No. of total patients No. of patients with a
positive RT-PCR assay
Positive bone scan (Ml b) 9 5
Negative bone scan (MO)
TlaNO 0 0
T1bNO 4 0
T1cNO 1 0
T2aNO 5 0
T2bNO 4 0
T2cNO 4 2
T3aNO 1 0
T3bNO 3 2
T3cNO 3 2
T3cN1 1 1
aClinical staging was performed according to the TNM classification (Schoder
et al, 1992).
tumours underwent the operation within 1 month of bone marrow
aspiration without the neoadjuvant hormonal therapy.
Bone marrow specimens
Approximately 5 ml of bone marrow was aspirated from the ante-
rior or posterior iliac crest and collected in a tube containing
EDTA. The marrow specimen was layered on a Lymphoprep
density gradient (Nycomed Pharma, Oslo, Norway) and
centrifuged at 1800 r.p.m. for 20 min. The cell layer at the inter-
face was collected and washed once in phosphate-buffered saline
(PBS). The cells were then subjected to the RT-PCR assay.
RT-PCR assay
Messenger RNA was extracted from the cells isolated from bone
marrow and cDNA was synthesized from the isolated mRNA as
previously described (Deguchi et al, 1993). PCR amplification
with PSA-A1 andPSA-B, primers and hybridization analysis with
the internal probe was performed in accordance with the previous
protocol (Deguchi et al, 1993). The integrity of mRNA isolated
from the specimens was examined by RT-PCR with primers for
human 0-actin (Deguchi et al, 1993). The bone marrow specimens
for which the expected 754-bp DNA fragment hybridizing to the
internal probe was amplified were regarded as positive for PSA
mRNA expression (Deguchi et al, 1993). In this study, the pres-
ence of PSA mRNA in the bone marrow was referred to as
micrometastases. Positive control reactions for the RT-PCR were
performed using mRNA isolated from prostate specimens.
Negative control reactions were performed using all of the
reagents as for the clinical specimens, but without addition of
mRNA, in each ofthe assays. To minimize contamination, sample
preparations and RT-PCR were performed using precautionary
procedures as suggested by Kwok (1990).
Statistical methods
Statistical analysis was conducted using the Wilcoxon rank-sum
test and Fisher's exact test. All statistical comparisons were two-
tailed and performed with significance set at P<0.05.
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Table 2 Serum PSA concentration in 35 patients examined for bone
metastases bone scan imaging and RT-PCR assay
Bone metastasis No. of total patients PSA (ng ml-')
Range Median
Positive bone scan 9 25.0-1187.0a 100.0
Negative bone scan 26 0.8-380.0a 12.8
Positive RT-PCR 7 10.9-380.0b 30.0
Negative RT-PCR 19 0.8-174.0b 8.3
aWilcoxon rank-sum test, P<0.01. b Wilcoxon rank-sum test, P<0.01. 000A0
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Figure 2 Distribution of serum PSA concentrations c
order. 0, Patients had metastatic bone diseases det(
scans and RT-PCR assays. *, Patients had bone m
bone scans, but no bone marrow micrometastases d
assays. A, Patients with negative bone scans had bi
micrometastases detected by RT-PCR assays. 0, P
metastatic bone disease detected by bone scans or
y-axis is on a log scale. The broken line indicates a F
RESULTS
Detection of bone metastases using b
Of 35 patients, nine patients had positive
bone scans. Ofthese nine patients, five had e)
multiple bones, including the pelvis, and ft
radionuclide uptake in a few ribs and/or ver
involvement.
Detection of PSA mRNA expression in
using the RT-PCR assay
In all patients, prostate specimens and prost
confirmed to express PSA at the mRNA anm
RT-PCR and immunohistochemistry. The comparison between the
clinical stages of 35 patients and the results ofthe RT-PCR assays
for PSA mRNA expression in the bone marrow is presented in
Table 1. Of nine patients with positive bone scan findings, five
(56%) had PSA mRNA expression in the bone marrow detected by
A, ,0' ,35 RT-PCR. All of these patients had extensive metastatic disease
25 30 35 involving the pelvic bones. The remaining four patients had no
pelvic metastases and PSA mRNA expression was not detected.
One patient with regional lymph node metastases and four (57%)
ected byboth bone of seven patients with locally extensive prostate cancer (T3
ietastases detected by tumour) had PSA mRNA expression detected in the bone marrow.
letected by RT-PCR Two (15%) of 13 patients with clinically localized prostate cancer
atients had no (T2 tumour) had PSA mRNA expression detected in the bone
RT-PCR assays. The marrow (Figure 1). In five patients with early-stage prostate
PSA level of 25 ng ml-' cancer, PSA mRNA expression was not detected.
In this study, 13 patients with negative bone scan findings under-
went prostatectomy with pelvic lymphadenectomy. Two patients
with T3 tumours underwent the surgery after 3 months' neoadju-
vant hormone therapy; one had tumour extending through the
tone scan Imaging prostate capsule and invading the bladderneck with no histological
findings detected on evidence of lymph node metastases (pT4apNO), and the other
xtensive metastases in patient had histological evidence of invasion of the seminal vesi-
our had an increased cles and metastases to the regional lymph nodes (pT3cpN2c).
tebrae without pelvic These two patients had positive RT-PCR assays. One patient with
clinically localized prostate cancer (T2c tumour) underwent radical
prostatectomy with pelvic lymphadenectomy without neoadjuvant
bone marrow hormonetherapy, and his tumour washistologically confined to the
prostate with no histological evidence of lymph node metastases
(pT2cpNO). This patient also had PSA mRNA expression detected
tate cancer cells were in the bone marrow. The remaining ten patients who had histo-
d protein levels using logically organ-confined diseases had negative RT-PCR assays.
Table 3 Performance profiles of bone scan, bone marrow aspiration (RT-PCR assay) and determination of serum PSA concentrations in predicting bone
involvement, including micrometastases in 35 patients with prostate cancera
Positive predictive Negative predictive
value (95% lower value (95% lower
Assay Sensitivity Specificity and upper and upper
confidence limits) confidence limits)
Bone scan 56.3% (9/16) 100% (19/19) 100% (9/9) 73.1% (19/26)
(56.0-90.1%)
RT-PCR 75.0% (12/16) 100% (19/19) 100% (12/12) 82.6% (19/23)
(67.1-98.1%)
PSA (25 ng ml-1 87.5% (14/16) 89.5% (17/19) 87.5% (14/16) 89.5% (17/19)
or greater) (71.3-100%) (75.7-100%)
aln addition to positive bone scan findings, the presence of PSA mRNA in the bone marrow was regarded as bone micrometastases.
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Correlation between bone involvement and serum PSA
concentration
Serum PSA concentrations were elevated in 31 (89%) of 35
patients. The results ofthe comparison between bone involvement,
including micrometastasis, and serum PSA concentration are
summarized in Table 2. Serum PSA concentrations (median 100.0
ng ml-1) of patients with positive bone scan findings were signifi-
cantly higher than those (median 12.8 ng ml-') in the patients
without positive findings (Wilcoxon rank sum test, P<0.01). In
patients with negative bone scan findings, serum PSA concentra-
tions (median 30.0 ng ml-') of patients with positive RT-PCR
assays were significantly higher than those (median 8.3 ng ml-') of
patients with negative RT-PCR assays (Wilcoxon rank-sum test,
P<0.01). The distribution of serum PSA concentrations of all
patients is presented in rank order (Figure 2). Of 16 patients with a
serum PSA concentration of 25 ng mlF1 or greater, nine (56.3%)
patients had bone metastases detected by bone scans whereas,
among 19 patients with a serum PSA concentration of less than 25
ng ml-', none had evidence of bone metastases on bone scans.
However, of seven patients with a serum PSA concentration of 25
ng ml' or greater and no bone metastases detected by bone scans,
five had bone marrow micrometastases detected by RT-PCR.
Therefore, 14(87.5%) of 16 patients with a serum concentration of
25 ng ml' or greater had metastatic bone diseases including
micrometastases. In addition, out of 19 patients with a serum PSA
concentration of less than 25 ng ml' and negative bone scan find-
ings, two (10.5%) patients had PSA mRNA expression in the bone
marrow detected by RT-PCR. These two patients underwent
prostatectomy with pelvic lymphadenectomy after 3 months'
neoadjuvant hormone therapy. Their pathological stages were
pT4apNO for one patient with a serum PSA concentration of 10.9
ng ml' and pT3cpN2c for the other patient with a serum concen-
tration of 17.0 ng ml-'. Overall,patients with a serum PSA concen-
tration of 25 ng ml-' or greater had a significantly higher risk of
bone involvement than those with a serum PSA concentration of
less than 25 ng ml' (Fisher's exact test, P<0.0001).
Based on the assumption that the presence ofPSA mRNA in the
bone marrow can be referred to as bone micrometastases, Table 3
presents performance profiles of bone scan, bone marrow aspira-
tion (RT-PCR assay) and determination of serum PSA concentra-
tions in predicting bone involvement in the patients recruited for
this study. The sensitivity and specificity for a serum PSA concen-
tration of 25 ng ml-' or greater were 87.5% and 89.5% respec-
tively. The positive predictive value was 87.5%, and the lower and
upper 95% confidence limits were 71.3% and 100% respectively.
The negative predictive value was 89.5%, with the 95% confi-
dence limits being 75.7% (lower) and 100% (upper). The sensi-
tivity and negative predictive value were higher than those ofbone
scan and bone marrow aspiration in predicting metastatic bone
diseases.
DISCUSSION
We developed the RT-PCR assay to detect metastatic prostate
cancer cells (Deguchi et al, 1993). The RT-PCR assay detects
PSA mRNA expression from mRNA corresponding to 0.1 LNCaP
prostate cancer cells and a single LNCaP cell mixed in 106 periph-
eral blood mononuclear cells. This assay has a higher sensitivity
than other conventional microscopic or immunocytochemical
techniques to detect prostate cancer cells in lymph nodes. In this
study, 35 bone marrow specimens obtained from previously
untreated prostate cancerpatients were examinedforexpressionof
PSA mRNA using this RT-PCR assay. In 7 of 26 patients with
negative bone scans, the RT-PCR assay detected PSA mRNA
expression in the bone marrow. Of seven patients with positive
RT-PCR assays, five patients had locally extensive prostate
cancer, but two patients had clinically or histologically localized
prostate cancer. In previous studies, immunocytochemistry
detected micrometastatic prostate cancer cells in the bone marrow
of 19.5% ofthe patients with localized prostate cancer (Obermeder
et al, 1994), and another RT-PCR assay, specific for PSA mRNA,
also found occult bone marrow micrometastases in 20% of
patients with pathologically confined prostate cancer (Wood et al,
1994b). These findings together with the results of our study
demonstrate that micrometastases are present in the bone marrow
of patients with clinically and/or pathologically localized prostate
cancer. Although not yet conclusive, a small number of PSA-
expressing cells detected by RT-PCR in the bone marrow could
constitute clinically significant bone metastases. The detection of
micrometastatic cells in the bone marrow ofpatients withoperable
breast, gastrointestinal and non-small-cell lung cancer is a prog-
nostic indicator ofearly relapse (Cote et al, 1991; Schlimok et al,
1991; Lindenmann et al, 1992; Pantel et al, 1993). Therefore, in
patients with prostate cancer, the detection ofPSA mRNA expres-
sion using RT-PCR should be useful indetermining thepossibility
of curative surgery or in identifying patients at risk of metastatic
diseases.
As demonstrated in this study, the largest concern regarding the
clinical use of this method is its site-specific sensitivity. Of nine
patients with positive bone scans, four patients had no expression
of PSA mRNA in the bone marrow detectedby RT-PCR. In these
fourpatients, metastases were found in a few ribs and/or vertebrae
without involvement of the pelvic bones, compared with the five
patients with positive RT-PCR that had extensive metastases on
bone scans found in multiple bones including the pelvic bones.
Immunocytochemistry detected metastatic prostate cancer cells in
the bone marrow of 57.1-100% of the patients with overt bone
metastases (Mansi etal, 1988; Bretton etal, 1994; Oberneder etal,
1994). Another RT-PCR assay detected PSA mRNA in all five
patients with metastatic diseases (Wood et al, 1994b). That assay
detected a single LNCaP cell out of 106 cells ofperipheral blood
mononuclear cells with asensitivity equal to our assay (Deguchi et
al, 1993; Wood et al, 1994a). In the previous reports, information
concerning the extent of metastatic disease or the presence or
absence of pelvic bone metastases was not available, but two or
more aspirates were taken from various sites of the iliac crests
and/or the sternum for immunocytochemistry or RT-PCR (Mansi
et al, 1988; Bretton et al, 1994; Wood et al, 1994b). In our study,
only one bone marrow aspirate was obtained from one site of the
iliac crest for RT-PCR. Therefore, to facilitate the clinical utility
of bone marrow aspiration for the detection of micrometastases,
multiple sampling of bone marrow from various sites will be
needed. Otherwise, a more sensitive RT-PCR assay involving
nested PCR strategies may be required to increase the sensitivity
(Israeli et al, 1994; Eschwege et al, 1995).
A statistically significant difference was observed in the distribu-
tion of serum PSA concentrations between patients with positive
bone scan findings and those with negative findings. In patients
with negative bone scans, a significant difference was also found
between patients withpositive RT-PCR assays and those with nega-
tive assays. These findings were in concordance with a previous
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bone micrometastasis study using RT-PCR (Wood et al, 1994a).
Recently, the negative predictive value (99.7%) ofa low serum PSA
concentration for bone scan findings has been demonstrated
(Chybowski et al, 1991), but an elevated serum PSA concentration
has not been predictive of bone metastases in individual cases
(Osterling 1991; Kleer et al, 1993). However, this study has demon-
strated that patients with a serum PSA concentration of25 ng ml-' or
greater had a significantly higher probability of bone involvement
and that the sensitivity and negative predictive value for a serum
PSA concentration of 25 ng ml-' or greater in predicting metastatic
bone diseases were higher than those ofbone scan and bone marrow
aspiration. Therefore, these findings suggest that a high serum
PSA concentration might be the most useful indicator of bone
involvement, in clinical terms, for patients with prostate cancer.
Methods such as RT-PCR which have the ability to detect a tumour
burden, including micrometastases, will facilitate the establishment
ofa precise correlation between serum PSA concentration and clin-
ical stage.
Limitations of our study include the small sample size and
insufficient information about the clinical significance of bone
marrow micrometastases. Further studies with a large population
and with long-term follow-up of patients with bone marrow
micrometastases are needed. Nevertheless, this study suggests that
RT-PCR could potentially develop into a relevant tool for the
assessment of micrometastases to the bone and establish a precise
correlation between serum PSA concentration and bone involve-
ment in patients with prostate cancer.
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